Once More Into the Valley of Death: Navigating SBIR/STTR Funding for Tech Startups After 2025
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs were reauthorized through September 2031, adding a new Strategic Breakthrough Awards tier of up to $30 million for transformative technologies. Annual federal non‑dilutive capital now exceeds $4 billion, with cumulative investment of $70‑80 billion since inception. Phase I awards are capped at $314 k (NIH) and $275 k (NSF), while Phase II caps reach $2.1 million (NIH) and $1 million (NSF). Success hinges on robust IP strategies and can be amplified by state matching programs, as Ohio and other states demonstrate.
Sex-Related Differences in Immune System Aging May Impact Disease Susceptibility
Researchers at Barcelona Supercomputing Center used single‑cell RNA sequencing on nearly 1,000 blood samples to map how immune aging differs between men and women. The analysis revealed that women experience a pronounced increase in inflammatory immune cells with age, which...
Quarterly Inactive Ingredient Database (IID) Change Log
The FDA’s Inactive Ingredient Database (IID) is updated each quarter, and the Change Log records all corrected, deleted, and Maximum Daily Exposure (MDE) replacement entries. The log spans 2020‑2026, with file sizes ranging from 21 KB to 357 KB, reflecting the volume...
Salk to Lead $41.3M ARPA-H Effort to Advance Sonogenetics Therapies
The Salk Institute secured a $41.3 million ARPA‑H award to advance sonogenetics, a technique that uses low‑intensity ultrasound to control engineered cellular proteins. Over the next five years, Salk’s Dr. Sreekanth Chalasani and a multi‑institutional team will develop ultrasound‑responsive proteins, wearable...
AACR 2026: Professional Awards Acknowledge Community’s Contributions to Cancer Research
The American Association for Cancer Research unveiled its 2026 professional award winners at the San Diego meeting (April 17‑22). Honorees span the spectrum of oncology, from James P. Allison’s seminal CTLA‑4 work to the Broad Institute’s Cancer Dependency Map team that charted...
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
The FDA issued final guidance titled “Cannabis and Cannabis‑Derived Compounds: Quality Considerations for Clinical Research,” clarifying how sponsors can use both hemp and cannabis with THC levels above 0.3% in human drug trials. The guidance outlines source options—including the NIDA...
Review and Approval
The FDA approves biosimilars through an abbreviated pathway that relies on demonstrating high similarity to an existing reference biologic, rather than repeating full safety and efficacy trials. Manufacturers must provide analytical, animal, and clinical data, and the agency can waive...
Advancing Fully Walkaway Automation in Genomics Workflows
SPT Labtech and the European Molecular Biology Laboratory’s GeneCore facility in Heidelberg have partnered to install the firefly®+ all‑in‑one liquid‑handling platform, aiming to deliver fully walkaway automated genomics workflows. The system combines pipetting, dispensing, incubation and shaking, and will run...
Vivatides Therapeutics Raises $54M for RNA Expansion
Vivatides Therapeutics announced a $54 million Series A round, led by Qiming Venture Partners and backed by several other investors. The funding will accelerate its proprietary extrahepatic delivery platform, designed to transport RNA molecules such as siRNA and antisense oligonucleotides beyond the...
Minimally-Invasive Stenting Effectively Treats Painful Post-Thrombotic Syndrome
Washington University researchers led the NIH‑funded C‑TRACT trial, showing that minimally invasive venous stenting markedly improves outcomes for patients with post‑thrombotic syndrome. Among 225 participants with severe disease, stent plus standard therapy reduced the persistence of severe syndrome to 40%...
TANGENT Phase 3 Study Meets Primary and Secondary Endpoints, SynOx Reports
SynOx Therapeutics reported that its Phase 3 TANGENT study of emactuzumab met both primary and secondary endpoints in tenosynovial giant cell tumor (TGCT). The five‑dose, eight‑week regimen achieved statistically significant RECIST responses and tumor volume reductions at six months. Patients also...
F.D.A. Calls on Drug Developers to Publish Missing Data From Thousands of Trials
The FDA announced it has dispatched more than 2,200 letters to drug makers, device manufacturers and researchers, demanding the publication of clinical‑trial results that remain absent from ClinicalTrials.gov. An internal analysis shows roughly 30 % of studies under FDA review have...
ROIS Expands US Injectable Manufacturing Capacity
ROIS has completed the acquisition of a 370,000‑square‑foot injectable manufacturing facility in Phoenix, Arizona, adding high‑potent fill/finish and lyophilization capabilities for biologics and antibody‑drug conjugates (ADCs). The site already holds FDA, EMA and Japanese regulatory approvals, enabling immediate support for...
FDA Narrows in on Search for New Biologics and Vaccines Leader
The U.S. Food and Drug Administration is close to naming a new director for its Center for Biologics Evaluation and Research (CBER), ending the turbulent tenure of Vinay Prasad. Sources say the leading candidate is Dr. Susan K. Lee, a...
October - December 2022 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System...
The FDA’s Adverse Event Reporting System (FAERS) prompted a wave of labeling revisions between 2023 and 2025, adding new safety warnings to dozens of drugs. Notable changes include hypersensitivity alerts for cabotegravir injectables, fecal incontinence risks for several atypical antipsychotics,...
A Novel Approach To The Treatment Of Antibiotic Resistant Infections
Researchers have engineered microscopic, cell‑like particles that hunt drug‑resistant bacteria while sparing healthy microbes. The particles use protein‑based recognition to bind unique bacterial markers and deliver toxic proteins or bactericidal chemicals in a two‑step process. Laboratory tests showed a single...
NHS Improves Genetic Testing for Minority Ethnic Cancer Patients
The NHS has expanded its pre‑chemotherapy genetic screening to include a fifth DPYD gene variant that is more common among Black and minority‑ethnic patients. Previously, tests only covered four variants prevalent in white European populations, leaving many patients at risk...
Sibel Health Wins FDA Clearance for Maternal-Fetal Monitoring Platform
Sibel Health announced FDA 510(k) clearance for ANNE Maternal, a wireless wearable that continuously monitors a pregnant woman's vital signs, fetal heart rate, and uterine activity. The platform adds visual and audio alarms plus an automated Modified Early Obstetric Warning...
Person Functionally Cured of HIV After Bone Marrow Transplant From Sibling
A 63‑year‑old man achieved functional cure of HIV after receiving a bone‑marrow transplant from his brother, who carries two copies of the CCR5 Δ32 mutation that blocks the virus’s primary entry point. The donor cells fully engrafted in the recipient’s blood,...
Appointments and Advancements for April 13, 2026
On April 13, 2026 three biotech firms filed patents on novel drug candidates. Accure Therapeutics disclosed oligopeptide derivatives that inhibit matrix metalloproteinases MMP‑2 and MMP‑9, enzymes linked to cancer invasion and fibrosis. Merck Sharp & Dohme (MSD) introduced indazole‑based blockers of HCN1/2...
Allogene’s First Cut of Data on ‘Off-the-Shelf’ CAR-T Shows Promise
Allogene Therapeutics reported that its off‑the‑shelf CAR‑T candidate cleared all detectable lymphoma cells in just over half of trial participants. The interim analysis stems from the pivotal ALLO‑501/ALLO‑501A study in relapsed or refractory B‑cell lymphoma. Researchers highlighted a complete molecular...
GSK Reports Strong Results for B7-H4 ADC in Gynecological Cancers
GSK’s investigational antibody‑drug conjugate mocertatug rezetecan (Mo‑Rez) demonstrated robust activity in its Phase 1 BEHOLD‑1 trial, achieving a 62% objective response rate in platinum‑resistant ovarian cancer and 67% in recurrent or advanced endometrial cancer. The drug targets the B7‑H4 immune checkpoint,...
USP Adds Tamiflu, Trulicity to Vulnerable List as Upstream Analysis Reshapes Supply Concerns
The United States Pharmacopeia (USP) has refreshed its vulnerable medicines list, adding Tamiflu (oseltamivir) and Trulicity (dulaglutide) after expanding its risk assessment to include key starting materials (KSMs). The new analysis shows 48 of the 100 flagged drugs depend on...
Allogene Stock Sails After CAR T Clears Residual Lymphoma in Early Data Cut
Allogene Therapeutics reported interim results from its Phase 2 ALPHA3 trial showing its off‑the‑shelf CAR‑T product cema‑cel cleared measurable residual disease in 58.3% of patients versus 16.7% in the observation arm. The therapy also achieved a 97.7% drop in circulating tumor...
How This Biotech Stock Skirted Today's Selloff
Revolution Medicines (RVMD) surged 35.5% to $131.35, briefly touching a record $135.81 after reporting that its pancreatic‑cancer pill daraxonrasib cut death risk by 60% in a Phase 3 trial. Leerink and Guggenheim raised price targets to $147 and $174, respectively. The...
Hidden Antivirals Discovered in a Plant-Derived Supplement
Researchers identified a new family of trace molecules, dubbed dicitriosides, hidden in a 90 %‑purity isoquercitrin supplement. These triterpenoid‑cinnamate compounds exhibit nanomolar potency against Ebola, Zika and SARS‑CoV‑2, outperforming the original mixture by roughly 25‑fold. The antiviral activity was isolated to...
BioNTech's HER2 ADC Succeeds in Phase 2 Study, FDA Filing Planned
BioNTech announced that its HER2‑targeted antibody‑drug conjugate, trastuzumab pamirtecan (formerly BNT323), achieved robust efficacy in a Phase 2 trial of HER2‑positive metastatic breast cancer. The study reported a 45% overall response rate and a median progression‑free survival of 8.2 months, with...
Revolution Rises 40% as Pancreatic Cancer Drug Doubles Survival
Revolution Medicines announced that its oral RAS inhibitor daraxonrasib doubled overall survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma, achieving 13.2 months versus 6.7 months on chemotherapy. The Phase 3 RASolute 302 interim analysis was declared final, prompting the company...
The AI Value Gap and Why Validation Is a Practical First Win for Life Sciences
AI adoption in life‑sciences is hampered by a wide value gap, with only about 40% of firms seeing EBIT impact and most gains under 5%. A practical entry point is FDA‑oriented computer system validation (CSV) and computer software assurance, where...
IDEAYA/Servier PKC Drug Aces Uveal Melanoma Trial
IDEAYA’s PKC inhibitor darovasertib, combined with Pfizer’s crizotinib, achieved a statistically significant improvement in progression‑free survival in the phase 2/3 OptimUM‑02 trial for HLA‑A*02:01‑negative metastatic uveal melanoma. Median PFS extended to 6.9 months versus 3.1 months for investigator‑chosen immunotherapy, and the...
STAT+: Pharmalittle: We’re Reading About a Pancreatic Cancer Pill, FDA Rejecting a Replimune Drug Again, and More
Revolution Medicines reported that its KRAS‑targeting oral pill daraxonrasib more than doubled median overall survival for metastatic pancreatic cancer patients, achieving 13.2 months versus 6.7 months on standard chemotherapy. The company will leverage a FDA priority‑review voucher to seek accelerated...
AbbVie Enters World of Pain in up to $715M Deal with China’s Haisco
AbbVie has signed an exclusive licensing agreement with China’s Haisco Pharmaceutical Group that could be worth up to $715 million. The deal grants AbbVie rights to a portfolio of pain‑related compounds ranging from preclinical to Phase 1 stages in China. This marks...
Amgen Pipeline’s Next Growth Cycle: Replacing Its Old Blockbusters
Amgen posted $36.8 billion in 2025 revenue, a 10% year‑on‑year rise, but its legacy blockbusters such as Enbrel, Xgeva and Otezla are under pressure from biosimilars and U.S. pricing reforms. Growth is now being driven by cardiovascular drugs, rare‑disease assets acquired...
Pharma Firms Accelerate Regional Capacity Building to Secure GLP-1 Supply and Mitigate Geopolitical Risks
Pharma companies are reshaping supply chains by regionalizing GLP‑1 manufacturing to mitigate geopolitical risks and meet soaring demand for metabolic therapies. Eli Lilly announced a $3 billion investment in China and a ¥20 billion ($126 million) upgrade of its Kobe plant in Japan, targeting...
Regeneron Enters Radiopharma Ring with up to $4.3B Telix Alliance
Regeneron Pharmaceuticals has struck a partnership with Australian biotech Telix, committing $40 million to launch four initial radiopharmaceutical programs and securing an option for four more. The deal splits development and commercialization costs and profits equally, while Telix stands to earn...
Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs Viral Infection Results in Approximately 20 Minutes
Beckman Coulter Diagnostics, a Danaher company, received CE Mark approval for the Access MeMed BV assay, a high‑throughput host‑response test that distinguishes bacterial from viral infections in about 20 minutes. The assay runs on existing DxI 9000 and Access 2...
STAT+: Revolution Medicines Touts ‘Unprecedented’ Data for Pancreatic Cancer Pill
Revolution Medicines reported that its oral KRAS‑G12C inhibitor daraxonrasib more than doubled survival for patients with metastatic pancreatic cancer. In a head‑to‑head trial, the daily pill yielded a median overall survival of 13.2 months versus 6.7 months for standard chemotherapy....
The Era of Big Pharma’s One-Size-Fits-All Pipeline Is Fading
Big Pharma’s pipeline volume remained steady in early 2026, but its composition is fragmenting. While the ten largest developers still dominate, the number of boutique firms with one or two candidates surged past 4,000, reflecting investor appetite for niche innovation....
Haisco Partners with AbbVie to Develop Novel Medicines for Pain in a ~$745M Deal
Haisco Pharma signed an exclusive licensing agreement with AbbVie to develop, manufacture and commercialize novel pain medicines outside China, Hong Kong and Macau. The deal provides Haisco with a $30 million upfront payment and up to $715 million in development, regulatory and...
STAT+: Allogene Therapeutics’ CAR-T Treatment Eliminates Residual Cancer Cells in B-Cell Lymphoma Patients
Allogene Therapeutics reported that its off‑the‑shelf CAR‑T therapy, cema‑cel, eliminated residual cancer cells in B‑cell lymphoma patients at three times the rate of standard care, meeting the interim goal of its Phase 3 trial. In the interim analysis, 58% of treated...
NICE Update Doubles Eligible Patients for AZ's Lokelma
NICE’s draft guidance doubles the number of patients in England and Wales who can receive AstraZeneca’s Lokelma for hyperkalaemia. The eligibility threshold was lowered from a serum potassium level of 6.0 mmol/L to 5.5 mmol/L, and the specialist‑only initiation rule was removed....
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
NeoGenomics, a leading oncology diagnostics firm, will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego. The abstracts focus on merging laboratory testing with real‑world clinical data to power AI‑driven biomarker analysis...
Scientists Are Trying to Build a Vaccine that Works Against Almost Any Respiratory Pathogen — Here's How Close They Are.
Scientists at Stanford have engineered an experimental nasal spray that activates the lungs' innate immune system rather than targeting specific antigens. In mouse studies the spray slashed viral loads by roughly 700‑fold and bacterial counts by 200‑fold, while also dampening...
STAT+: Spyre Therapeutics IBD Drug Shows Promise in Early Trial
Spyre Therapeutics reported positive Phase 2 data for its ulcerative colitis candidate SPY001, showing safety and meeting the trial's primary endpoint. In the SKYLINE study, patients experienced a 9.2‑point drop in a disease‑activity index, and roughly 40% entered remission after 12...
Did Neuralink Make the Wrong Bet?
Elon Musk’s Neuralink has long marketed brain‑computer interfaces that let users move a cursor with thought, but rivals are now delivering speech‑based BCIs that translate neural signals directly into words. The article argues that Neuralink’s focus on cursor control is...
Ideaya’s Uveal Melanoma Drug Exceeds Success Benchmark in Late-Stage Trial
Ideaya BioSciences reported that its late‑stage drug for uveal melanoma met its pre‑specified success benchmark, achieving a 27% overall response rate versus the 20% target. The trial also demonstrated a manageable safety profile, reinforcing confidence in the therapy’s risk‑benefit balance....
Structural Elucidation and Antidiabetic Activity of Polysaccharides From the Parasitic Plant Orobanche Cumana
Researchers isolated three polysaccharide fractions from the parasitic plant Orobanche cumana and identified the alkaline‑extracted fraction OCP‑3 as a low‑molecular‑weight rhamnogalacturonan‑I‑rich polysaccharide. OCP‑3 showed strong antioxidant activity and inhibited key carbohydrate‑digesting enzymes, with IC₅₀ values of 98.5 µg mL⁻¹ for α‑amylase and...
BIO Coffee Chat Explores Venture Philanthropy
The Biotechnology Innovation Organization (BIO) hosted a Patient Advocacy Coffee Chat highlighting the growing influence of venture philanthropy in biotech. Patient groups are now acting as investors, using capital and disease expertise to de‑risk early‑stage programs and guide trial design....
This Method to Reverse Cellular Aging Is About to Be Tested in Humans
Researchers at the Whitehead Institute have engineered a three‑gene cocktail that partially reprograms aged retinal nerve cells, reversing age‑related damage in mouse eyes. The breakthrough underpins Life Biosciences' first human clinical trial, which will deliver the Yamanaka factors—minus the oncogenic...
A New Wave of Immunotherapy Is Eliminating Cancers
Immunotherapy, especially checkpoint inhibitors like dostarlimab, is delivering unprecedented tumor regressions, with recent trials reporting complete remission in 84% of participants. The approach offers non‑surgical, low‑toxicity alternatives, as illustrated by patients such as Maureen Sideris whose esophageal cancer vanished after...
